Lobbying registration dated 2026-03-03
Registrant: Sridhar Venkatesh
Client: GlaxoSmithKline Inc.
Targeted institutions:
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Indigenous Services Canada (ISC)
Pacific Economic Development Canada (PacifiCan)
Global Affairs Canada (GAC)
Patented Medicine Prices Review Board (PMPRB)
Canadian Heritage (PCH)
Justice Canada (JC)
Finance Canada (FIN)
House of Commons
Employment and Social Development Canada (ESDC)
Veterans Affairs Canada (VAC)
Public Health Agency of Canada (PHAC)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Correctional Service of Canada (CSC)
Prime Minister's Office (PMO)
Innovation, Science and Economic Development Canada (ISED)
Immigration, Refugees and Citizenship Canada (IRCC)
Legislative bills: C-51
Acts: Patent Act
Food and Drugs Act
Government funding received:
Lobbying activity details:
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada
The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004.
Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.
Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development.
Engagement with the Government regarding the Strategic Innovation Fund
Trade-related matters, including policies and tariffs impacting medicines and vaccines.
Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians.
Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.
Engage with government to strengthen the Priority Review for Drug Submissions process.
Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process.
Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. 
Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.
Engagement with federal officials regarding Health Emergency Readiness Canada.
Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding.
National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada.
Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. 
Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
Policies and programs related to the health of new immigrants to Canada.
Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada.
Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030.
Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada.
FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions